Ace Therapeutics, a premier preclinical CRO, announces its dedicated preclinical ophthalmic drug development services to help expedite the discovery and development of cutting-edge treatments for ocular diseases. At the core of innovation and compliance is Ace Therapeutics, which assists pharma and biotech firms to launch successful ophthalmic therapies.
The development of drugs for the treatment of ocular diseases is accompanied by several hurdles such as the anatomical and physiological complexity of the eye, the massive regulatory demands, and the importance of targeted drug delivery. But advances in drug delivery, biologics, and gene therapy are creating opportunities for improved treatments. As an experienced provider of preclinical ophthalmology CRO services, Ace Therapeutics offers end-to-end preclinical services tailored to ophthalmic drug development, including:
Disease modeling for conditions such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, dry eye disease, and uveitis.
Pharmacokinetics (PK) and pharmacodynamics (PD) studies to assess drug absorption, distribution, and efficacy in ocular tissues.
Toxicology and safety evaluations to ensure compliance with FDA, EMA, and other regulatory guidelines.
Formulation optimization for topical, intravitreal, and sustained-release drug delivery systems.
Biomarker identification and efficacy testing using advanced in vitro and in vivo models.
Ace Therapeutics’ Cutting-Edge Expertise in Ophthalmology
Supported by experienced scientists and with in-house state-of-the-art facilities, Ace Therapeutics uses advanced ocular disease models and translational research to reduce attrition between preclinical and clinical success. Its capabilities cover small and large compounds, gene therapies, and new drug delivery systems.
“Ophthalmic indications pose a variety of drug development challenges, from bioavailability to targeted delivery,” added the business development manager at Ace Therapeutics. “Our preclinical ophthalmic capabilities are all about delivering robust and high-quality data that de-risks development and speeds the road to IND acceptance.”
Ace Therapeutics collaborates with biopharmaceutical companies worldwide to advance next-generation ophthalmic treatments. By integrating customized study designs, advanced imaging technologies, and regulatory support, the company helps clients optimize their candidates for clinical trials. For more information on Ace Therapeutics' preclinical ophthalmic drug development services, visit www.acetherapeutics.com/ophthalmology.
About Ace Therapeutics
Ace Therapeutics is a research service provider specializing in ophthalmology. It provides researchers around the globe with comprehensive solutions for ophthalmic drug discovery and preclinical development. Backend with scientific expertise and cutting-edge equipment, Ace Therapeutics’ services span in vivo ocular efficacy studies, bioanalysis, and various preclinical studies designed to support the development of ophthalmic drugs.
Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email:Send Email
Phone: 15164410167
Country: United States
Website: https://www.acetherapeutics.com/